You get an FDA approval, you get an FDA approval… Everybody gets an FDA approval!

10 minute read


Catch up on some of the latest approvals from the US Food and Drug Administration.


The FDA aren’t putting their feet up as we approach the end of 2026 – find out on some of what they’ve been up to. 

New ground for symptomatic dermographism treatment 

Symptomatic dermographism is a common form of chronic inducible urticaria (hives) characterised by the raised, red, and itchy welts that form when the skin is scratched, rubbed, or otherwise has pressure applied to it. It is primarily managed using H1 antihistamines, but treatment options were limited for patients who failed to respond to, or had an inadequate response to, antihistamines.  

Now, remibrutinib (Rhapsido, Novartis), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi) has received FDA approval for its use in the treatment of adults with SD. The BTK pathway is involved in histamine release, a key driver of the hives and swelling seen in SD. 

“Remibrutinib offers, for the first time, an approach to treatment specifically for SD patients who remain inadequately controlled with H1 antihistamines alone, representing a meaningful step forward for this population,” said Professor Giselle Mosnaim, an allergist and immunologist from the University of Chicago Pritzker School of Medicine.  

The decision to expand the approval of remibrutinib came after the FDA assessed the results of SD patients from the phase III RemIND trial – a year-long, double-blind, placebo-controlled study – where 115 adults with SD (mean age 39.2 years, 71.3% female, mean SD duration of 5.8 years) received either 25mg of remibrutinib or placebo twice a day for 24 weeks.  

All patients had been diagnosed with SD for at least four months, were unable to adequately control their disease with H1 antihistamines, and had a Total Fric Score ≥3 on the Fric Test 4.0. 

The primary endpoint – the proportion of patients with a complete response in Total Fric Score (i.e., 0) at week 12 – favoured remibrutinib over placebo (29.3% versus 14.0%). This difference remained after 24 weeks of treatment (32.8% versus 15.8%). Patients were able to achieve a complete response in as little as two weeks of treatment.   

Common side effects associated with remibrutinib include nasal congestion, sore throat, runny nose, bleeding, headache, nausea, and abdominal pain.  

The FDA’s decision follows the 2025 approval of remibrutinib for use in the treatment of adults with chronic spontaneous urticaria, making it the only treatment to be given an indication for both forms of chronic hives. Remibrutinib has also been approved in Europe and China for the treatment of adults with CSU that is inadequately controlled by H1 antihistamines. The TGA approved remibrutinib for the treatment of adults with CSU who remain symptomatic despite H1 antihistamine treatment in May 2026.   

The RemIND study also investigated the efficacy of remibrutininb in other kinds of chronic inducible urticaria, including cold urticaria and cholinergic urticaria. In its statement, Novartis indicated it planned to submit the complete RemIND dataset to health authorities across the globe (where appropriate) – suggesting it may only be a matter of time before the company seeks approval for remibrutinib in the treatment of SD in Australia.   

Combination maintenance therapy for HER2-positive breast cancer can now be used as first-line treatment 

After previously receiving FDA approval as a second-line therapy in 2020, tucatinib (Tukysa, Pfizer) in combination with trastuzumab and pertuzumab has now been granted approval for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2-positive) breast cancer following induction treatment.  

Efficacy data were obtained through the HER2CLIMB-05 phase III trial. As part of this trial, 654 adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer (median age 54 years) with no evidence of disease progression after undergoing four to eight cycles of trastuzumab, pertuzumab, and a taxane received either 300mg of tucatinib or placebo twice daily with trastuzumab and pertuzumab administered intravenously. Participants could also be randomised to receive a fixed-dose combination of trastuzumab, pertuzumab, and hyaluronidase, which was also administered subcutaneously.  

Median progression-free survival was 24.9 months in the tucatinib arm and 16.3 months in the placebo arm (hazard ratio and 95% confidence interval 0.64, 0.51-0.80). The association between tucatinib and progression-free survival was maintained regardless of whether asymptomatic brain metastases were present or not.  

Common treatment-emergent adverse events in the tucatinib arm were diarrhoea (72.7%), nausea (33.1%), and elevated liver enzymes (alanine aminotransferase [28.2%] and aspartate aminotransferase [25.8%]). Thirteen percent of patients in the tucatinib arm discontinued treatment because of treatment-emergent adverse events.   

“The treatment landscape for HER2+ metastatic breast cancer has evolved dramatically over the past decade, but many patients still experience disease progression despite initial benefit from therapy,” said Dr Erika Hamilton, chief development officer and late phase & research director of Breast Cancer Research for the Sarah Cannon Research Institute. Dr Hamilton was also the principal investigator of the HER2CLIMB-05 trial.  

“The HER2CLIMB-05 findings support tucatinib plus trastuzumab and pertuzumab as a chemotherapy-free maintenance strategy that allows us to target HER2-positive tumours from multiple angles and can help prolong disease control.” 

Tucatinib, in combination with trastuzumab and capecitabine, received TGA approval for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer – including patients with brain metastases – who have received one or more previous anti-HER2-based regimens in the metastatic setting in August 2020.  

Novel chronic hepatitis B treatment gets green light 

Bepirovirsen (Hibsago, GSK), an antisense oligonucleotide injection administered in combination with existing antiviral therapy, recently received FDA approval for the treatment of chronic hepatitis B virus in select adults without cirrhosis. 

Specifically, adults need to have been taking hepatitis B antiviral therapy for at least six months, have suppressed viral levels in their blood, and hepatitis B surface antigen levels ≤ 3000IU/ml. 

Bepirovisen acts by targeting the genetic instructions the hepatitis B virus uses to replicate itself and its viral proteins, thereby lowering the amount of the virus and the hepatitis B surface antigen in the body. 

The FDA’s decision was informed by the results of a pair of phase III trials, published in the New England Journal of Medicine earlier this year, that compared subcutaneous bepirovirsen injections against placebo injections over a 24-week period. Participants were randomised in a 2:1 fashion across the two trials, with 1223 patients receiving bepirovirsen and 611 receiving placebo. 

The proportion of patients who were functionally cured at week 72 – defined as at least 24 weeks of having a sustained hepatitis B virus level below the lower limit of quantification and hepatitis B surface antigen loss after fixed-duration therapy – was larger for the bepriovirsen group compared to placebo in both trials (20% versus 0% and 19% versus 0%).  

Pooled safety data from the two trials revealed that 89% of patients in the bepirovirsen group and 65% of patients in the placebo group experienced at least one adverse event. A larger proportion of adverse events in the bepirovirsen group were deemed to be treatment-related compared to placebo (80% versus 35%), although serious adverse events were rare (4% and 1%, respectively).    

Dr Wendy Carter, an infectious disease specialist and acting director of the Office of Infectious Diseases in the Center of Drug Evaluation and Research, said many individuals living with chronic hepatitis B were required to take antiviral medication for years to keep the virus suppressed. 

“Hibsago provides a new treatment approach that gives some patients the possibility of maintaining control of the virus after all chronic HBV treatment has ended. This approval represents an important advance for people living with this serious disease,” she said in a statement. 

Bepirovirsen is currently under evaluation by the TGA for the treatment of chronic hepatitis B virus in adults without liver cirrhosis and the same additional criteria outlined by the FDA approval. The application was accepted in June 2026.  

Dozen up for atezolizumab 

Finally, the FDA approved the use of atezolizumab (Tecentriq, Genentech, Inc.) in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and paediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer – as well as atezolizumab and hyaluronidase-tqjs in combination with the same two chemotherapy agents for the adjuvant treatment of adult and paediatric patients aged 12 years and older who weigh ≥40kgs with stage III dMMR colon cancer. 

The approval was the twelfth indication for atezolizumab in the United States. 

“This approval provides a new adjuvant treatment option for people with stage III dMMR colon cancer who face a high risk of disease recurrence,” said Levi Garraway, MD PhD, the chief medical officer and head of Global Product Development at Genentech. “Tecentriq combined with chemotherapy has the potential to become the new standard of care as the first approved immunotherapy-based regimen for this setting.” 

The evidence supporting the application came from the recent phase III ATOMIC study, published in the New England Journal of Medicine, where 712 patients (median age 64 years, 55.1% women) were treated with either atezolizumab and a combination of fluorouracil, oxaliplatin, and leucovorin or the combination of the three agents alone. 

After median follow-up of 40.9 months, the three-year disease-free survival rate was 86.3% in the atezolizumab group and 76.2% in the control group (hazard ratio and 95% confidence interval for disease recurrence or death 0.50, 0.35-0.73). Grade 3 or 4 adverse events occurred in 84.1% of patients who received atezolizumab and the combination treatment compared to 71.9% of patients in the combination group alone. 

Professor Frank Sinicrope, a medical oncologist and gastroenterologist from the Mayo Clinic Comprehensive Cancer Center in the US, said that prior to the ATOMIC Trial the adjuvant standard of care for stage III dMMR colon cancer had not differed based on the patient’s mismatch repair status. 

“This milestone represents an important therapeutic advance that leverages immunotherapy to target the specific biology of dMMR stage III colon cancer after surgical resection,” the US principal investigator on the ATOMIC trial said in a statement. “By reducing the risk of disease recurrence or death by 50%, atezolizumab plus chemotherapy is a practice-changing regimen that can improve clinical outcomes of this group of patients living with colon cancer, one of the most common cancers and a leading cause of cancer-related death.”  

Atezolizumab, an anti-PD-L1 monoclonal antibody, has been approved by the TGA for use in the treatment of multiple kinds of cancer: non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, and urothelial carcinoma. 

Labelling changes for GLP1-RAs 

In early November the FDA released an alert regarding the labelling requirements for glucagon-like peptide-1 receptor agonists (GLP-1 RAs). 

All application holders for all GLP-1 RAs will be required to add information to the Warnings and Precautions section of their labelling regarding the potential increased risk of non-arteritic ischaemic optic neuropathy (NAION) that is associated with the use of these products.  

NAION is a rare condition that can lead to acute and painless decreased vision in one eye and can eventually result in permanent vision loss.  

“Health care professionals should be aware of the potential increased risk of rare NAION in patients treated with GLP-1 RAs,” the agency said in its statement. 

“Instruct patients to immediately report sudden onset of acute, painless, decreased vision; visual field deficits; or other visual disturbances in one eye. If NAION is suspected, promptly refer the patient to an ophthalmologist for evaluation. Consider discontinuing the GLP-1 RA in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk.” 

Read the full alert here. 

End of content

No more pages to load

Log In Register ×